Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Millennium Biotechnologies, a wholly owned subsidiary of Millennium Biotechnologies Group, has entered into a five-year exclusive distribution agreement for Resurgex, its nutritional formula for immuno- comprised patients, with Ferring Incorporated of Canada, a division of Ferring.
Subscribe to our email newsletter
Under the distribution agreement Ferring will have the exclusive right to use the Resurgex trademarks and sell the Resurgex line of products in Canada. Ferring will be responsible for the marketing, distribution and sales efforts throughout Canada putting Resurgex into the premium Enteral Nutritional Market. Ferring will purchase all products from Millennium Biotechnologies and will promote Resurgex to various specialist groups throughout Canada.
Mark Mirken, president and COO of Millennium Biotechnology, said: “Given the exhaustive evaluation, which they have conducted, and the size of their investment, this is a significant step for Millennium Biotechnologies in the international commercialization of our product line.”